

REACH: non-regulatory announcement

24 January 2025

**SOLVONIS THERAPEUTICS PLC**  
("Solvonis" or the "Company")

**Investor Presentation**

Solvonis Therapeutics plc (LON: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce that the Company will be presenting at MelloMonday on Monday 27 January 2025 which will take place as a webinar via Zoom. Anthony Tennyson, CEO, will be presenting and will take questions during the event.

For further information or if you would like to attend, please visit:

<https://melloevents.com/mm270125/> where you can register for a free ticket using the code **SHME100**.

**Enquiries:**

**Solvonis Therapeutics plc**

Anthony Tennyson, CEO & Executive Director

Email: [anthony@solvonis.com](mailto:anthony@solvonis.com)

**Allenby Capital (Financial Adviser and Broker)** +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

**About Solvonis Therapeutics plc**

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders. Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the US, UK and key EU markets.

[www.solvonis.com](http://www.solvonis.com) | [LinkedIn](#) | [X \(formerly Twitter\)](#)

**About Reach announcements**

This is an RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUOUWRVOUUAUR